Eprosartan Mesylate

HCID 5282474CAS 144143-96-4

기본 정보

표준 SMILES: CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
InChIKey: DJSLTDBPKHORNY-XMMWENQYSA-N
분자식: C24H28N2O7S2
평균 분자량: 520.6 g/mol
단동위원소 질량: 520.13379358

이름 및 식별자

우선 이름: Eprosartan Mesylate
IUPAC: 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid
영어명: Eprosartan mesylate
분자식: C24H28N2O7S2
분자량: 520.62

이름 및 동의어

EPROSARTAN MESYLATETevetenEprosartan mesilateeprosartan methanesulfonateEprosartan MonomethanesulfonateSK&F 108566-JDTXSID7044217UNII-8N2L1NX8S3SK&F-108566-J8N2L1NX8S3DTXCID5024217CHEBI:48409

이름 더 보기

Eprosartan MyslateEposartan mesylateMonomethanesulfonateEprosartanMesylate>Eprosartan mesylate, >=99%Eprosartan mesylate USP/EP/BPSunitinib and its interMediate

(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonateTEVETEN HCT COMPONENT EPROSARTAN MESYLATE2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonateEPROSARTAN MESILATE (MART.)EPROSARTAN MESILATE [MART.]EPROSARTAN MESYLATE (USP-RS)EPROSARTAN MESYLATE [USP-RS](E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate

데이터베이스 식별자

CAS: 144143-96-4
PubChem CID: 5282474
DTXSID: DTXSID7044217
ChEMBL: CHEMBL1200987
ChEBI: CHEBI:48409
UNII: 8N2L1NX8S3

물성

구조 계산 물성

극성 표면적: 183 Å²
수소 결합 공여자 수: 3
수소 결합 수용자 수: 9
회전 가능 결합 수: 10
무거운 원자 수: 35
형식 전하: 0
복잡도: 711

물리화학적 성질

녹는점: 248 · 248-250°
저장 조건: Sealed in dry,Room Temperature
용해도: 10 mg/mL · DMSO: >10mg/mL
물리적 상태: 가루
색상: 흰색에서 황백색까지
Merck: 14 · 14,3635
주요 응용: 의약품(소분자)
InChIKey: DJSLTDBPKHORNY-XMMWENQYSA-N
SMILES: S(O)(=O)(=O)C.C(C1C=CC(C(=O)O)=CC=1)N1C(=NC=C1/C=C(/C(=O)O)\CC1SC=CC=1)CCCC

화학적 성질

White to Off-White Solid

안전 및 규제

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Eprosartan mesylate

Ambiguous-DILI-concern

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 1건

◉ Summary of Use during Lactation；Eprosartan is no longer marketed in the US. Because no information is available on the use of eprosartan during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.